Streptococcus pneumoniae

Streptococcus pneumoniae
S. pneumoniae in spinal fluid. FA stain (digitally colored).
Scientific classification
Domain: Bacteria
Phylum: Firmicutes
Class: Cocci
Order: Lactobacillales
Family: Streptococcaceae
Genus: Streptococcus
Species: S. pneumoniae
Binomial name
Streptococcus pneumoniae
(Klein 1884)
Chester 1901

Streptococcus pneumoniae, or pneumococcus, is a Gram-positive, alpha-hemolytic (under aerobic conditions) or beta-hemolytic (under anaerobic conditions), facultative anaerobic member of the genus Streptococcus.[1] As a significant human pathogenic bacterium S. pneumoniae was recognized as a major cause of pneumonia in the late 19th century, and is the subject of many humoral immunity studies.

S. pneumoniae resides asymptomatically in healthy carriers typically colonizing the respiratory tract, sinuses, and nasal cavity. However, in susceptible individuals with weaker immune systems, such as the elderly and young children, the bacterium may become pathogenic and spread to other locations to cause disease. It can be a cause of neonatal infections.[2]

S. pneumoniae is the main cause of community acquired pneumonia and meningitis in children and the elderly,[3] and of septicemia in those infected with HIV. The organism also causes many types of pneumococcal infections other than pneumonia. These invasive pneumococcal diseases include bronchitis, rhinitis, acute sinusitis, otitis media, conjunctivitis, meningitis, sepsis, osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis, cellulitis, and brain abscess.[4]

S. pneumoniae can be differentiated from the viridans streptococci, some of which are also alpha-hemolytic, using an optochin test, as S. pneumoniae is optochin-sensitive. S. pneumoniae can also be distinguished based on its sensitivity to lysis by bile, the so-called "bile solubility test". The encapsulated, Gram-positive coccoid bacteria have a distinctive morphology on Gram stain, lancet-shaped diplococci. They have a polysaccharide capsule that acts as a virulence factor for the organism; more than 90 different serotypes are known, and these types differ in virulence, prevalence, and extent of drug resistance.

History

In 1881, the organism, known later in 1886 as the pneumococcus[5] for its role as a cause of pneumonia, was first isolated simultaneously and independently by the U.S. Army physician George Sternberg[6] and the French chemist Louis Pasteur.[7]

The organism was termed Diplococcus pneumoniae from 1920[8] because of its characteristic appearance in Gram-stained sputum. It was renamed Streptococcus pneumoniae in 1974 because it was very similar to streptococci.[5][9]

S. pneumoniae played a central role in demonstrating that genetic material consists of DNA. In 1928 Frederick Griffith demonstrated transformation of life turning harmless pneumococcus into a lethal form by co-inoculating the live pneumococci into a mouse along with heat-killed virulent pneumococci.[10] In 1944 Oswald Avery, Colin MacLeod, and Maclyn McCarty demonstrated the transforming factor in Griffith's experiment was not protein, as was widely believed at the time, but DNA.[11] Avery's work marked the birth of the molecular era of genetics.[12]

Genetics

The genome of S. pneumoniae is a closed, circular DNA structure that contains between 2.0 and 2.1 million base pairs depending on the strain. It has a core set of 1553 genes, plus 154 genes in its virulome, which contribute to virulence and 176 genes that maintain a noninvasive phenotype. Genetic information can vary up to 10% between strains.[13]

Transformation

Natural bacterial transformation involves the transfer of DNA from one bacterium to another through the surrounding medium. Transformation is a complex developmental process requiring energy and is dependent on expression of numerous genes. In S. pneumoniae at least 23 genes are required for transformation. In order for a bacterium to bind, take up and recombine exogenous DNA into its chromosome it must enter a special physiological state called competence.

Competence in S. pneumoniae is induced by DNA-damaging agents such as mitomycin C, fluoroquinolone antibiotics (norfloxacin, levofloxacin and moxifloxacin), and topoisomerase inhibitors.[14] Transformation protects S. pneumoniae against the bactericidal effect of mitomycin C.[15] Michod et al.[16] summarized evidence that induction of competence in S. pneumoniae is associated with increased resistance to oxidative stress and increased expression of the RecA protein, a key component of the recombinational repair machinery for removing DNA damages. On the basis of these findings they suggested that transformation is an adaptation for repairing oxidative DNA damages. S. pneumoniae infection stimulates polymorphonuclear leukocytes (granulocytes) to produce an oxidative burst that is potentially lethal to the bacteria. The ability of S. pneumoniae to repair the oxidative DNA damages in its genome, caused by this host defense, likely contributes to this pathogen’s virulence. Consistent with this premise Li et al.[17] reported that, among different highly transformable S. pneumoniae isolates, nasal colonization fitness and virulence (lung infectivity) depend on an intact competence system.

Infection

S. pneumoniae is part of the normal upper respiratory tract flora. As with many natural flora it can become pathogenic under the right conditions, typically when the immune system of the host is suppressed. Invasins, such as pneumolysin, an anti-phagocytic capsule, various adhesins, and immunogenic cell wall components are all major virulence factors. Once it colonizes the alveoli the body responds by stimulating the inflammatory response causing plasma, blood, and white blood cells to fill the alveoli. This condition is called pneumonia.[18] It is susceptible to clindamycin.[19]

Vaccine

Due to the importance of disease caused by S. pneumoniae several vaccines have been developed to protect against invasive infection. The World Health Organization recommend routine childhood pneumococcal vaccination;[20] it is incorporated into the childhood immunization schedule in a number of countries including the United Kingdom,[21] United States,[22] and South Africa.[23]

Interaction with Haemophilus influenzae

Historically Haemophilus influenzae (H. influenzae) has been a significant cause of infection and both H. influenzae and S. pneumoniae can be found in the human upper respiratory system. A study of competition in vitro revealed S. pneumoniae overpowered H. influenzae by attacking it with hydrogen peroxide.[24] However, in a study adding both bacteria to the nasal cavity of a mouse within 2 weeks only H. influenzae survives; further analysis showed that neutrophils exposed to dead H. influenzae were more aggressive in attacking S. pneumoniae.[25]

Diagnosis

Diagnosis is generally made based on clinical suspicion along with a positive culture from a sample from virtually any place in the body. An ASO Titre of >200 units is significant.[4] S. pneumoniae is, in general, optochin sensitive, although optochin resistance has been observed.[26]

Atromentin and leucomelone possess antibacterial activity, inhibiting the enzyme enoyl-acyl carrier protein reductase, (essential for the biosynthesis of fatty acids) in S. pneumoniae.[27] Optochin sensitivity in a culture of Streptococcus pneumoniae

See also

References

  1. ↑ Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology. McGraw Hill. ISBN 0-8385-8529-9.
  2. ↑ Baucells, B.J.; Mercadal Hally, M.; Álvarez Sánchez, A.T.; Figueras Aloy, J. (2015). "Asociaciones de probióticos para la prevención de la enterocolitis necrosante y la reducción de la sepsis tardía y la mortalidad neonatal en recién nacidos pretérmino de menos de 1.500g: una revisión sistemática". Anales de Pediatría. ISSN 1695-4033. doi:10.1016/j.anpedi.2015.07.038.
  3. ↑ van de Beek, Diederik; de Gans, Jan; Tunkel, Allan R.; Wijdicks, Eelco F.M. (5 January 2006). "Community-Acquired Bacterial Meningitis in Adults". New England Journal of Medicine. 354 (1): 44–53. ISSN 0028-4793. PMID 16394301. doi:10.1056/NEJMra052116. Retrieved 15 February 2017.
  4. 1 2 Siemieniuk, Reed A.C.; Gregson, Dan B.; Gill, M. John (Nov 2011). "The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study". BMC Infectious Diseases. 11: 314. PMC 3226630 Freely accessible. PMID 22078162. doi:10.1186/1471-2334-11-314.
  5. 1 2 Plotkin, SA; Orenstein, W; Offit, PA (September 22, 2012). Vaccines. Elsevier – Saunders. p. 542. ISBN 978-1455700905. Retrieved July 2, 2015.
  6. ↑ Sternberg, George Miller (30 April 1881). "A fatal form of septicaemia in the rabbit produced by the subcutaneous injection of human saliva. An experimental research". Bulletin of the National Board of Health. Baltimore, Maryland.
  7. ↑ Pasteur, Louis (1881). "Sur une maladie nouvelle provoquée par la salive d'un enfant mort de rage". Comptes rendus de l'Académie des Sciences de Paris. Paris, France. 92: 159.
  8. ↑ Winslow, C.; J. Broadhurst (1920). "The Families and Genera of the Bacteria: Final Report of the Committee of the Society of American Bacteriologists on Characterization and Classification of Bacterial Types". J Bacteriol. 5 (3): 191–229. PMC 378870 Freely accessible. PMID 16558872.
  9. ↑ Wainer H (2014). Medical Illuminations: Using Evidence, Visualization and Statistical Thinking to Improve Healthcare. Oxford University Press. p. 53. ISBN 978-0199668793. Retrieved July 4, 2015.
  10. ↑ Griffith F (January 1928). "The Significance of Pneumococcal Types" (PDF). Journal of Hygiene. Cambridge University Press. 27 (2): 113–159. PMC 2167760 Freely accessible. PMID 20474956. doi:10.1017/S0022172400031879. Retrieved July 3, 2015.
  11. ↑ Avery OT, MacLeod CM, McCarty M (1944). "Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III". J Exp Med. 79 (2): 137–158. PMC 2135445 Freely accessible. PMID 19871359. doi:10.1084/jem.79.2.137.
  12. ↑ Lederberg J (1994). "The Transformation of Genetics by DNA: An Anniversary Celebration of Avery, Macleod and Mccarty (1944)". Genetics. 136 (2): 423–6. PMC 1205797 Freely accessible. PMID 8150273.
  13. ↑ van der Poll T, Opal SM (2009). "Pathogenesis, treatment, and prevention of pneumococcal pneumonia". Lancet. 374 (9700): 1543–56. PMID 19880020. doi:10.1016/S0140-6736(09)61114-4.
  14. ↑ Claverys JP, Prudhomme M, Martin B (2006). "Induction of competence regulons as a general response to stress in gram-positive bacteria". Annu. Rev. Microbiol. 60: 451–75. PMID 16771651. doi:10.1146/annurev.micro.60.080805.142139.
  15. ↑ Engelmoer DJ, Rozen DE (December 2011). "Competence increases survival during stress in Streptococcus pneumoniae". Evolution. 65 (12): 3475–85. PMID 22133219. doi:10.1111/j.1558-5646.2011.01402.x.
  16. ↑ Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens" (PDF). Infect. Genet. Evol. 8 (3): 267–85. PMID 18295550. doi:10.1016/j.meegid.2008.01.002.
  17. ↑ Li G, Liang Z, Wang X, Yang Y, Shao Z, Li M, Ma Y, Qu F, Morrison DA, Zhang JR (2016). "Addiction of Hypertransformable Pneumococcal Isolates to Natural Transformation for In Vivo Fitness and Virulence". Infect. Immun. 84 (6): 1887–901. PMC 4907133 Freely accessible. PMID 27068094. doi:10.1128/IAI.00097-16.
  18. ↑ Anderson, Cindy. "Pathogenic Properties (Virulence Factors) of Some Common Pathogens" (PDF).
  19. ↑ "Clindamycin" (PDF). Davis. 2017. Retrieved March 24, 2017.
  20. ↑ "Pneumococcal vaccines WHO position paper--2012" (PDF). Wkly Epidemiol Rec. 87 (14): 129–44. Apr 6, 2012. PMID 24340399.
  21. ↑ "Children to be given new vaccine". BBC News. 8 February 2006.
  22. ↑ "Pneumococcal Vaccination: Information for Health Care Providers". cdc.org. Retrieved 26 July 2016.
  23. ↑ "Critical decline in pneumococcal disease and antibiotic resistance in South Africa". NICD. Retrieved 20 July 2015.
  24. ↑ Pericone, Christopher D.; Overweg, Karin; Hermans, Peter W. M.; Weiser, Jeffrey N. (2000). "Inhibitory and Bactericidal Effects of Hydrogen Peroxide Production by Streptococcus pneumoniae on Other Inhabitants of the Upper Respiratory Tract". Infect Immun. 68 (7): 3990–3997. PMC 101678 Freely accessible. PMID 10858213. doi:10.1128/IAI.68.7.3990-3997.2000.
  25. ↑ Lysenko ES, Ratner AJ, Nelson AL, Weiser JN (2005). "The Role of Innate Immune Responses in the Outcome of Interspecies Competition for Colonization of Mucosal Surfaces". PLoS Pathog. 1 (1): e1. PMC 1238736 Freely accessible. PMID 16201010. doi:10.1371/journal.ppat.0010001. Full text
  26. ↑ Pikis, Andreas; Campos, Joseph M.; Rodriguez, William J.; Keith, Jerry M. (2001). "Optochin Resistance in Streptococcus pneumoniae: Mechanism, Significance, and Clinical Implications". The Journal of Infectious Diseases. Oxford University Press. 184 (5): 582–90. ISSN 0022-1899. JSTOR 30137322. PMID 11474432. doi:10.1086/322803. (Registration required (help)).
  27. ↑ Zheng CJ, Sohn MJ, Kim WG (2006). "Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae". Journal of Antibiotics. 59 (12): 808–12. PMID 17323650. doi:10.1038/ja.2006.108.
Wikimedia Commons has media related to Streptococcus pneumoniae.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.